A novel blood based surveillance test using artificial intelligence and next-generation sequencing identified relapse a median of 41 days before clinical detection in patients with AML or MDS ...
CareDx, Inc. ? The Transplant Companytm, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high?value healthcare solutions ...
Peer-reviewed Phase 2 Results Inform Ongoing Phase 3/Pivotal Trial of Celeste® in Parkinson’s Disease The Phase 2 study ...
Q4 2025 Management View CEO Brian Goff emphasized the company's 2026 strategic priorities, stating, "we're focused on executing a high-impact launch of AQVESME for the treatment of thalassemia in the ...
The only acceptable AI error rate is "zero," the health AI expert told Newsweek. But, he said, "We'll kind of never get there ...
Plaintiff's counsel have filed an amended complaint in the antitrust class action challenging U.S. Anesthesia Partners' ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results